Money Is Moving

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Director buying at Profound Medical (T:PRN)

Updated Wednesday Dec 05, 2018 02:39 AM EDT

Arun Menawat, a Senior Officer and Director, acquired 153,700 Common Shares on a direct ownership basis at prices ranging from $0.657 to $0.686 between December 3rd, 2018 and December 4th, 2018. This represents a $102,825 investment into the company's shares and an account share holdings change of 18.9%.

Profound Medical is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Profound Medical Corp., formerly Mira IV Acquisition Corp., is a capital pool company. The Company is a medical device company focused on prostate cancer care. Its product consists of common electronic components, capital equipment and disposables. The Company is developing and commercializing a minimally invasive procedure for patients with prostate cancer, the Transurethral Ultrasound Ablation-PRO (TULSA-PRO) system. Its technology combines magnetic resonance imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland delivered through the urethra. Its real-time, MRI guided ultrasound procedure (TULSA) ablates the whole prostate gland, from the inside out, in a single session. It has completed a Phase l International Clinical Trial. The Phase I trial has demonstrated that magnetic resonance (MR)-guided TULSA provides treatment planning, real-time thermal dosimetry and control of prostate ablation to within approximately 1.3 millimeters.

INK Edge Outlook

6 months ago
1 year ago
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at
Two-week free trial for first time users.
Go to Profound Medical Corp. (PRN)'s company page

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).

Comment On!

No Comments


Search (past week) for $PRN.CA

  • No tweets found